In HSPCs of COVID-19, late-phase CD14+ monocytes retain elevated levels of inflammatory mediators such as S100A8 and S100A9 relative to both healthy controls and early-phase samples, underscoring their progression toward a more differentiated, pro-inflammatory phenotype (40). The gene discussed is S100A8; the disease is COVID-19.